Methylprednisolone Hemisuccinate
"Methylprednisolone Hemisuccinate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A water-soluble ester of METHYLPREDNISOLONE used for cardiac, allergic, and hypoxic emergencies.
Descriptor ID |
D008776
|
MeSH Number(s) |
D04.210.500.745.432.769.795.539.500
|
Concept/Terms |
Methylprednisolone Sodium Succinate- Methylprednisolone Sodium Succinate
- Sodium Succinate, Methylprednisolone
- Methylprednisolone Hemisuccinate Monosodium Salt
- 6 alpha-Methylprednisolone Sodium Hemisuccinate
- Methylprednisolone Sodium Hemisuccinate
- Sodium Hemisuccinate, Methylprednisolone
|
Below are MeSH descriptors whose meaning is more general than "Methylprednisolone Hemisuccinate".
Below are MeSH descriptors whose meaning is more specific than "Methylprednisolone Hemisuccinate".
This graph shows the total number of publications written about "Methylprednisolone Hemisuccinate" by people in this website by year, and whether "Methylprednisolone Hemisuccinate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 2 | 2 |
1998 | 0 | 1 | 1 |
1999 | 1 | 1 | 2 |
2001 | 0 | 1 | 1 |
2003 | 1 | 2 | 3 |
2008 | 0 | 1 | 1 |
2011 | 0 | 1 | 1 |
2012 | 1 | 0 | 1 |
2013 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Methylprednisolone Hemisuccinate" by people in Profiles.
-
Acute antibody-mediated rejection in pediatric kidney transplants: a single center experience. Pediatr Transplant. 2013 Nov; 17(7):E149-55.
-
Efficacy of intraoperative, single-bolus corticosteroid administration to prevent postoperative acute respiratory failure after oesophageal cancer surgery. Interact Cardiovasc Thorac Surg. 2012 Oct; 15(4):639-43.
-
Intramedullary PNET of the spine: long-term survival after combined modality therapy and subsequent relapse. J Pediatr Hematol Oncol. 2011 Mar; 33(2):107-12.
-
NMO antibody-positive recurrent optic neuritis without clear evidence of transverse myelitis. Arch Ophthalmol. 2008 Apr; 126(4):566-70.
-
Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions. Ann Pharmacother. 2003 Sep; 37(9):1182-5.
-
High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol. 2003 Jul; 121(7):944-9.
-
Heart xenograft survival with chimeric pig donors and modest immune suppression. Ann Surg. 2003 Feb; 237(2):265-72.
-
Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas. Int J Radiat Oncol Biol Phys. 2001 Jul 01; 50(3):743-9.
-
ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease. Blood. 1999 Jun 01; 93(11):3632-6.
-
Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sj?gren syndrome. Ophthalmology. 1999 Apr; 106(4):811-6.